Empiric micafungin didn't save lives in ICU-acquired sepsis
www.pulmccm.org
The antifungal micafungin is often given empirically to patients in ICUs with sepsis who are also at high risk for invasive fungal infections. IDSA guidelines endorse the use of empiric antifungals for patients with unresolving ICU-acquired sepsis, but any benefits of this are unknown. A randomized trial
Empiric micafungin didn't save lives in ICU-acquired sepsis
Empiric micafungin didn't save lives in…
Empiric micafungin didn't save lives in ICU-acquired sepsis
The antifungal micafungin is often given empirically to patients in ICUs with sepsis who are also at high risk for invasive fungal infections. IDSA guidelines endorse the use of empiric antifungals for patients with unresolving ICU-acquired sepsis, but any benefits of this are unknown. A randomized trial
Comments on this post are for paid subscribers